C WorldWide Group’s Repros Therapeutics Inc. RPRX Stock Holding History

C WorldWide Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-200,000	Closed	-$1.49M	–	141
2015 Q3	$1.49M	Hold	200,000	–	–	0.03%	92
2015 Q2	$1.43M	Hold	200,000	–	–	0.02%	99
2015 Q1	$1.72M	Buy	200,000 +65,000	+48%	+$581K	0.02%	86
2014 Q4	$1.35M	Buy	+135,000	New	+$1.15M	0.02%	82

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

C WorldWide Group's RPRX Position: Q4 2015 in Review

C WorldWide Group sold out of Repros Therapeutics Inc. (RPRX) in Q4 2015, closing a stake of 200,000 shares — an estimated $1.49M sold.

C WorldWide Group first reported a position in RPRX in Q4 2014 and held it in 4 quarters. The position peaked at $1.72M in Q1 2015. 56 funds tracked by Wall St. Rank hold RPRX as of Q4 2015.

C WorldWide Group reported no remaining Repros Therapeutics Inc. position as of Q4 2015 after selling out during the quarter.
C WorldWide Group sold 200,000 Repros Therapeutics Inc. shares in Q4 2015, an estimated $1.49M.
C WorldWide Group first reported a position in Repros Therapeutics Inc. in Q4 2014 and held it in 4 quarters.
C WorldWide Group's Repros Therapeutics Inc. position peaked at $1.72M in Q1 2015.
56 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2015.

Based on C WorldWide Group's 13F filing for Q4 2015, filed 8 Feb 2016.